Terms: = Lung cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS
622 results:
1. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor lkb1 inhibits growth via the PIKFYVE lipid kinase.
Ferrarone JR; Thomas J; Unni AM; Zheng Y; Nagiec MJ; Gardner EE; Mashadova O; Li K; Koundouros N; Montalbano A; Mustafa M; Cantley LC; Blenis J; Sanjana NE; Varmus H
Proc Natl Acad Sci U S A; 2024 May; 121(21):e2403685121. PubMed ID: 38743625
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic implications of stk11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
Zheng J; Deng Y; Huang B; Chen X
Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
[TBL] [Abstract] [Full Text] [Related]
3. Effect of the stk11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
4. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
5. Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J; Demes MC; Jeroch J; Bräuninger A; Hartung K; Gerstenmaier U; Marienfeld R; Hillmer A; Bohn N; Lehning C; Ferch F; Wild P; Gattenlöhner S; Möller P; Klauschen F; Jung A
Pathol Oncol Res; 2024; 30():1611590. PubMed ID: 38605929
[TBL] [Abstract] [Full Text] [Related]
6. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract] [Full Text] [Related]
7. Impact of lkb1 status on radiation outcome in patients with stage III non-small-cell lung cancer.
Sitthideatphaiboon P; Nantavithya C; Chantranuwat P; Vinayanuwattikun C; Sriuranpong V
Sci Rep; 2024 Mar; 14(1):6146. PubMed ID: 38480816
[TBL] [Abstract] [Full Text] [Related]
8. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and stk11/KEAP1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract] [Full Text] [Related]
11. stk11/lkb1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract] [Full Text] [Related]
12. Adeno-to-squamous transition drives resistance to KRAS inhibition in lkb1 mutant lung cancer.
Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H
Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609
[TBL] [Abstract] [Full Text] [Related]
13. Carnosic Acid against lung cancer: Induction of Autophagy and Activation of Sestrin-2/lkb1/AMPK Signalling.
O'Neill EJ; Sze NSK; MacPherson REK; Tsiani E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396629
[TBL] [Abstract] [Full Text] [Related]
14. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract] [Full Text] [Related]
15. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
16. Influence of
Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
[TBL] [Abstract] [Full Text] [Related]
17. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell lung cancer.
van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE
Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729
[TBL] [Abstract] [Full Text] [Related]
18. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
19. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
20. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell lung cancer.
Ricciuti B; Lamberti G; Puchala SR; Mahadevan NR; Lin JR; Alessi JV; Chowdhury A; Li YY; Wang X; Spurr L; Pecci F; Di Federico A; Venkatraman D; Barrichello AP; Gandhi M; Vaz VR; Pangilinan AJ; Haradon D; Lee E; Gupta H; Pfaff KL; Welsh EL; Nishino M; Cherniack AD; Johnson BE; Weirather JL; Dryg ID; Rodig SJ; Sholl LM; Sorger P; Santagata S; Umeton R; Awad MM
J Clin Oncol; 2024 Apr; 42(11):1311-1321. PubMed ID: 38207230
[TBL] [Abstract] [Full Text] [Related]
[Next]
